Reported Highlights ECTRIMS 2019: Epidemiology & Treatment
EACCME Accredited webinar
A critical review by our ECF reporters of new data presented at ECTRIMS 2019 in Copenhagen in the fields of Epidemiology & Treatment
EACCME accreditation
This webinar is accredited by the European Accreditation Council for Continuing Medical Education (EACCME).
Log in or create an account to watch this content
Subscribe now and get unlimited access to all webinars and recordings.
Now Playing: Reported Highlights ECTRIMS 2019: Epidemiology & Treatment
Welcome & introductions
- Prof Dr Giancarlo Comi, Chairman of the Department of Neurology and Director of the Institute of Experimental Neurology, Vita-Salute San Raffaele University, Milan, Italy
Report on Epidemiology
- Dr Gloria Dalla Costa, MD, Clinical Research Unit on CNS Disorders and Clinical Neuroimmunology Research Unit, Institute of Experimental Neurology, San Raffaele Hospital, Milan, Italy
- Prof dr Gilles Edan, Chair of the Department of Neurosciences, Neurological Department, University Hospital Rennes, Rennes, France
Report on Treatment
- Dr Pietro Annovazzi, MD, UOC Centro SM - Neurologia II, ASST Valle Olona, Presidio Ospedaliero di Gallarate, Varese, Italy
- Prof dr Per Soelberg Sörensen, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
This webinar was made possible by a Global Medical Education Funding Agreement with Merck Serono S.P.A, Rome, Italy, an affiliate of Merck Healthcare KGAA, Darmstadt, Germany.
Report on Epidemiology (0:01:51 - 0:50:18)
Introduction (0:01:51 - 0:02:04)
Comorbidities (0:02:04 - 0:12:12)
- A large exploratory case-control study on the multiple sclerosis prodrome, A. Hapfelmeier, Munich, Germany (0:02:04 - 0:07:24)
- Cardiovascular disease in patients with multiple sclerosis: a nationwide cohort study in Sweden, F. Piehl, Stockholm, Sweden (0:07:24 - 0:09:40)
- The survival of patients with multiple sclerosis in Turkey, M. Kurtuncu, Istanbul, Turkey (0:09:40 - 0:12:12)
Pregnancy (0:12:12 - 0:21:45)
- Family planning decision making in people with multiple sclerosis, L. Lavorgna, Naples, Italy (0:12:12 - 0:15:42)
- An international registry tracking pregnancy outcomes in women treated with dimethyl fumarate, K. Hellwig, Bochum, Germany (0:15:42 - 0:17:25)
- Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and portpartum in women with MS, D. Landi, Rome, Italy (0:17:25 - 0:20:28)
- Pregnancy outcomes in patients treated with Ocrelizumab, C. Oreja-Guevara, Lyon, France (0:20:28 - 0:21:45)
Long-term natural history studies (0:21:45 - 0:34:07)
- 0:21:45 - 0:29:04: Long term outcomes. Changes in MS prognosis through the CIS Barcelona cohort: a 25-year tale (M. Tintore, Barcelona, Spain)
- 0:29:04 - 0:34:07: Radiologically isolated syndrome: a 10 year follow-up study to identify factors predicting a clinical event (C. Lebrun, Nice, France)
Environmental risk factors (0:34:07 - 0:40:49)
- 0:34:07 - 0:37:42: Serological response against HHV-6A is associated with increased risk for multiple sclerosis (A. Fogdell-Hahn, Stockholm, Sweden)
- 0:37:42 - 0:40:49: A large case-control study on vaccination as risk factor of multiple sclerosis (C. Gasperi, Munich, Germany)
Questions, discussion and wrap-up (0:40:49 - 0:50:18)
Report on Treatment (0:50:18 - 1:49:33)
Introduction (0:50:18 - 0:52:46)
New therapies (0:52:46 - 1:11:13)
- Efficacy and safety of Ofatumumab versus teriflunomide in RMS: phase 3 ASCLEPIOS I and II trials (0:52:46 - 0:58:33)
- Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group phase 3 OPTIMUM study (0:58:33 - 1:06:02)
- Siponimod delays the time to wheelchair in atients with SPMS: results from the EXPAND study (1:06:02 - 1:07:52)
- MESEMS: autologous mesenchymal stem cells for multiple sclerosis: a multi-center, randomized, double blind, cross-over phase 2 trial (1:07:52 - 1:11:13)
Lessons from registry studies (1:11:13 - 1:15:39)
- Impact of age on treatment decisions and adherence to therapy in patients with relapsing-remitting MS (1:11:13 - 1:12:58)
- Big multiple sclerosis data network: marginal structural models confirm the long-term impact of DMTs on disability progression (1:12:58 - 1:15:39)
Safety issues of MS therapies (1:15:39 - 1:26:52)
- B-cell therapies related hypogammaglobulinemia (1:16:46 - 1:20:50)
- PML (1:20:50 - 1:23:04)
- Disease activity after FTY stop (1:23:04 - 1:26:52)
Pregnancy issues of MS therapies (1:26:52 - 1:30:22)
- Fingolimod (1:26:52 - 1:28:08)
- Natalizumab (1:28:08 - 1:30:22)
Therapeutic options in NMO-SD (1:30:22 - 1:39:44)
- Inebilizumab (1:30:22 - 1:31:27)
- Satralizumab (1:31:27 - 1:34:32)
- Eculizumab (1:34:32 - 1:35:43)
- Tocilizumab (1:35:43 - 1:39:44)